Nasdaq Inc (NASDAQ:NDAQ) will host a webcast and conference call on June 3 at 1:00PM ET to discuss positive Phase 3 results for CAN-2409 in prostate cancer.
The therapy showed a 30% reduction in disease recurrence when added to standard radiation.
The event follows Dr. Theodore DeWeese’s ASCO 2025 presentation and features trial investigators Dr. John Sylvester and Dr. Ronald Tutrone.
Access details are available on Candel’s website, with a replay for 30 days post-event.